Ana Márcia Tomé Camargos1, Ana Carolina Oliveira Gonçalves1, Maurílio de Souza Cazarim2, Cristina Sanches1, Leonardo Régis Leira Pereira2, André Oliveira Baldoni3. 1. Federal University of São João Del-Rei (UFSJ), Rua Sebastião Gonçalves Coelho, 400, Bairro Chanadour, Divinópolis, MG, CEP: 35.501-296, Brazil. 2. Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (FCFRP-USP), Av. Bandeirantes, 3.900 Monte Alegre, Ribeirão Preto, SP, CEP: 14040-900, Brazil. 3. Federal University of São João Del-Rei (UFSJ), Rua Sebastião Gonçalves Coelho, 400, Bairro Chanadour, Divinópolis, MG, CEP: 35.501-296, Brazil. Electronic address: andrebaldoni@ufsj.edu.br.
Abstract
INTRODUCTION: DM spending in the world is high, and Brazilian studies of public spending caused by DM are scarce. OBJECTIVE: To estimate the annual direct cost for the municipal health sphere, related to DM2 treatment, in patients with and without glycemic control. METHOD: A cross-sectional study carried out in a city in the interior of Minas Gerais state, with patients with DM2, being municipal PHS users. Data were collected from the computerized system of the municipality and patient records, and analyzed using the IBM SPSS v.19 statistical package. The response variable was categorized into controlled A1c (≤7%) and uncontrolled A1c (>7%). RESULTS: Glycemic control in 56.6% of the patients was unsatisfactory; the mean cost of pharmacotherapy for DM2 was US$ 3.14 per year for patients in the control group and US$ 45.54 per year for uncontrolled patients. CONCLUSION: Patients with unsatisfactory glycemic control are more expensive for the municipal health system.
INTRODUCTION:DM spending in the world is high, and Brazilian studies of public spending caused by DM are scarce. OBJECTIVE: To estimate the annual direct cost for the municipal health sphere, related to DM2 treatment, in patients with and without glycemic control. METHOD: A cross-sectional study carried out in a city in the interior of Minas Gerais state, with patients with DM2, being municipal PHS users. Data were collected from the computerized system of the municipality and patient records, and analyzed using the IBM SPSS v.19 statistical package. The response variable was categorized into controlled A1c (≤7%) and uncontrolled A1c (>7%). RESULTS: Glycemic control in 56.6% of the patients was unsatisfactory; the mean cost of pharmacotherapy for DM2 was US$ 3.14 per year for patients in the control group and US$ 45.54 per year for uncontrolled patients. CONCLUSION:Patients with unsatisfactory glycemic control are more expensive for the municipal health system.
Authors: Thays S Mendonça; William N Oliveira; Vinícius S Belo; Eduardo S Silva; Mariana L Pereira; Paulo R Obreli-Neto; André O Baldoni Journal: Diabetol Metab Syndr Date: 2022-05-03 Impact factor: 5.395